EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Atorvastatin Attenuated the Inflammatory Outcomes of COVID-19: A Double-Blind, Randomized Controlled Trial

Hajar Shokri-Afra, Shahab Moghadam, Ziaeddin Oladi, Masoud Lotfizadeh, Mohammad Mehdi Mirforoughi, Mohammad-Hassan Arjmand, Ahmad Raeisi

Journal of Reports in Pharmaceutical Sciences · 2025

DOI: 10.5812/jrps-149927 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Reports in Pharmaceutical Sciences, 2025. Verfasst von Hajar Shokri-Afra und 6 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammation is a key feature of coronavirus disease 2019 (COVID-19). Atorvastatin may help reduce inflammation and limit viral infection.

Objectives

This study aimed to evaluate the effects of atorvastatin on inflammatory biomarkers and the clinical progression of COVID-19.

Methods

In this double-blind, randomized controlled trial (RCT), 81 PCR-confirmed COVID-19 patients with moderate pulmonary involvement were recruited. Participants were randomly assigned to receive atorvastatin (40 mg) or placebo daily for 14 days after fulfilling the inclusion criteria. Primary outcomes (inflammatory markers) and secondary outcomes (laboratory factors and clinical progression) were assessed every 7 days.

Results

No significant differences were observed between groups in the need for supplemental oxygen and oxygen saturation (SpO2) levels. However, the time to clinical improvement was shorter in those receiving atorvastatin, leading to earlier discharge. Nevertheless, no obvious differences were observed in laboratory parameters between groups. Our findings revealed that atorvastatin could meaningfully attenuate the inflammatory markers and improve lipid profiles, whereas the placebo group showed no significant changes, except for C-reactive protein (CRP) and interleukin-6 (IL-6).

Conclusions

Atorvastatin significantly and safely improved the inflammatory state of moderate COVID-19 infection. These findings suggest that atorvastatin may be considered as part of the treatment and/or follow-up protocol for such patients.

Zitieren

APA

Shokri-Afra, H., Moghadam, S., Oladi, Z., Lotfizadeh, M., Mirforoughi, M. M., Arjmand, M., & Raeisi, A. (2025). Atorvastatin Attenuated the Inflammatory Outcomes of COVID-19: A Double-Blind, Randomized Controlled Trial. Journal of Reports in Pharmaceutical Sciences. https://doi.org/10.5812/jrps-149927

Vancouver

Shokri-Afra H, Moghadam S, Oladi Z, Lotfizadeh M, Mirforoughi MM, Arjmand M, et al. Atorvastatin Attenuated the Inflammatory Outcomes of COVID-19: A Double-Blind, Randomized Controlled Trial. Journal of Reports in Pharmaceutical Sciences. 2025. doi:10.5812/jrps-149927

BibTeX
@article{ShokriAfra2025,
  author = {Shokri-Afra, Hajar and Moghadam, Shahab and Oladi, Ziaeddin and Lotfizadeh, Masoud and Mirforoughi, Mohammad Mehdi and Arjmand, Mohammad-Hassan and Raeisi, Ahmad},
  title = {Atorvastatin Attenuated the Inflammatory Outcomes of COVID-19: A Double-Blind, Randomized Controlled Trial},
  journal = {Journal of Reports in Pharmaceutical Sciences},
  year = {2025},
  doi = {10.5812/jrps-149927}
}
Kostenlos starten →